STELLUX® Chemi Ultrasensitive Active GLP-1 ELISA (7-36) amide

Catalog Number
80-GLP1AU-CH01
STELLUX® Chemi Ultrasensitive Active GLP-1 ELISA (7-36) amide
$595.00
  • Buy 5 for $565.00 each and save 6%
  • Buy 9 for $535.00 each and save 11%
  • Buy 13 for $505.00 each and save 16%
  • Buy 16 for $475.00 each and save 21%

The STELLUX® Chemi Ultrasensitive Active GLP-1 ELISA (7-36) amide is intended for the quantitative determination of GLP- 1 (7-36) amide in serum and plasma samples collected in the presence of DPP-IV inhibitor.


Sample Volume: 25 µL


Sensitivity: < 0.06 pM


Specificity: 100% for GLP-1 (7-36 amide); Non Detect for other forms

Availability: Approximate Lead Time is 1-2 Weeks

Request a Quote
OR
Quote Request

Product: STELLUX® Chemi Ultrasensitive Active GLP-1 ELISA (7-36) amide

Catalog#: 80-GLP1AU-CH01


Billing Address


Shipping Address

Same as Billing Address
Specifications

Additional Information

Catalog # 80-GLP1AU-CH01
Species Human, Mouse, Rat
Regulatory Status Research Use Only. Not for Use in Diagnostic Procedures.
Product Distribution Available Worldwide
Range 0.23 - 314 pM (0.76 - 1036 pg/mL)
Sensitivity < 0.06 pM (0.2 pg/mL)
Sizes 96 Wells
Sample Types EDTA Plasma, Serum
Sample Size 25 µL
Protocol Click here to view
MSDS Click here to view
Additional Information

Glucagon-like peptide-1 (GLP-1) is an extensively well-characterized incretin hormone which regulates both insulin and glucagon secretion. GLP-1 is a highly sought after therapeutic target due to its beneficial effects on glucose homeostasis, particularly through regulation of beta cell mass, function, and viability.  GLP-1 is produced in intestinal L-cells in response to food and is well conserved across species. GLP-1 is derived from the cleavage of proglucagon to generate a 1-37 amino acid peptide. Fasting reduces circulating levels of GLP-1. GLP-1 has many physiological effects on the body.  Diabetes and obesity scientists have been using two main  GLP-1 research approaches: DPP-4 inhibition and GLP-1 analogs. DPP-4 can inactivate GLP-1 to its forms of GLP-1 (9-36) amide and GLP-1 (9-37) amide.  By inhibiting DPP-4, scientists hope that GLP-1 can continue to influence insulin secretion and restore balance to energy homeostasis.  The goal of developing GLP-1 analogs is to engineer a better GLP-1 molecule that has a longer half-life, thus providing longer influences over insulin secretion.


Currently available commercial ELISAs require large sample volumes or specialized instrumentation in order to achieve the desired sensitivity and to detect fasting levels of circulating GLP-1. Moreover, the variability within these assays, along with the lack of linearity and spike and recovery can, in many cases, lead to questions with regard to accuracy - even between different lots of the same kit. Keeping the aforementioned in mind, ALPCO has developed the STELLUX® Chemi Ultrasensitive Active GLP-1 ELISA (7-36) amide for the quantitative determination of GLP- 1 (7-36) amide in serum and plasma samples collected in the presence of DPP-IV inhibitor. Using a 25 μL sample size, this novel assay demonstrates excellent sensitivity of less than 0.25 pM, while specifically measuring GLP-1 (7-36) amide without any cross-reactivity to GLP-1 (1-36) amide, (1-37), (7-37), or (9-36). Specific detection of GLP-1 (7-36) amide is critical, as it is the major circulating biologically active fragment. Sequence conservation of GLP-1 across multiple species has enabled us to develop a single, low-volume assay which can discern fasted and fed levels in both human and rodent models. Most importantly, lack of matrix interference evaluated via dilutional linearity and spike and recovery studies ensures accuracy and precision.

Related Products